+

WO2000071154A3 - Adjuvant a stabilite et biocompatibilite optimisees pour l'augmentation de la reponse immunitaire humorale et cellulaire - Google Patents

Adjuvant a stabilite et biocompatibilite optimisees pour l'augmentation de la reponse immunitaire humorale et cellulaire Download PDF

Info

Publication number
WO2000071154A3
WO2000071154A3 PCT/EP2000/004565 EP0004565W WO0071154A3 WO 2000071154 A3 WO2000071154 A3 WO 2000071154A3 EP 0004565 W EP0004565 W EP 0004565W WO 0071154 A3 WO0071154 A3 WO 0071154A3
Authority
WO
WIPO (PCT)
Prior art keywords
sba
immune response
adjuvant
cellular immune
biocompatibility
Prior art date
Application number
PCT/EP2000/004565
Other languages
German (de)
English (en)
Other versions
WO2000071154A2 (fr
Inventor
Rainer Helmut Mueller
Nikolaus Grubhofer
Carsten Olbrich
Original Assignee
Pharmasol Gmbh
Rainer Helmut Mueller
Nikolaus Grubhofer
Carsten Olbrich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmasol Gmbh, Rainer Helmut Mueller, Nikolaus Grubhofer, Carsten Olbrich filed Critical Pharmasol Gmbh
Priority to MXPA01011660A priority Critical patent/MXPA01011660A/es
Priority to BR0010823-5A priority patent/BR0010823A/pt
Priority to KR1020017014653A priority patent/KR20020012221A/ko
Priority to AU52142/00A priority patent/AU5214200A/en
Priority to CA002373239A priority patent/CA2373239A1/fr
Priority to JP2000619456A priority patent/JP2003500365A/ja
Priority to EP00936761A priority patent/EP1183045A2/fr
Publication of WO2000071154A2 publication Critical patent/WO2000071154A2/fr
Publication of WO2000071154A3 publication Critical patent/WO2000071154A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un adjuvant à stabilité et biocompatibilité optimisées servant à augmenter la réponse immunitaire humorale et cellulaire par injection conjointe avec un ou plusieurs antigènes. L'adjuvant selon l'invention est constitué de particules à base de lipides ou de mélanges lipidiques solides et convient à la production de vaccins plus efficaces et mieux tolérés, aux vaccinations des hommes et des animaux, mais également à l'obtention d'anticorps. On peut moduler de manière ciblée la force de la réponse immunitaire par le choix de la taille et de la charge des particules ainsi que des propriétés de surface, et l'adapter ainsi à chaque espèce. On peut ajouter à l'adjuvant biocompatible stable (SBA) selon l'invention d'autres adjuvants comme, par exemple, des adjuvants moléculaires tels que le GMDP, ce qui entraîne en outre l'augmentation de la réponse immunitaire cellulaire. L'adjuvant biocompatible stable selon l'invention est plus puissant, moins coûteux et d'utilisation plus simple que les produits existant déjà ; en outre, il est bien toléré in vivo.
PCT/EP2000/004565 1999-05-20 2000-05-19 Adjuvant a stabilite et biocompatibilite optimisees pour l'augmentation de la reponse immunitaire humorale et cellulaire WO2000071154A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
MXPA01011660A MXPA01011660A (es) 1999-05-20 2000-05-19 Adyuvante optimizado en estabilidad y biocompatibilidad (sba) para aumentar la respuesta inmune humoral y celular.
BR0010823-5A BR0010823A (pt) 1999-05-20 2000-05-19 Adjuvante de estabilidade, biocompatibilidade otimizada (sba) para realçar a resposta imune humoral e celular
KR1020017014653A KR20020012221A (ko) 1999-05-20 2000-05-19 체액성 및 세포성 면역 반응을 증진시키기 위한, 안정성과생체 적합성이 최적화된 애쥬반트
AU52142/00A AU5214200A (en) 1999-05-20 2000-05-19 Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response
CA002373239A CA2373239A1 (fr) 1999-05-20 2000-05-19 Adjuvant a stabilite et biocompatibilite optimisees pour l'augmentation de la reponse immunitaire humorale et cellulaire
JP2000619456A JP2003500365A (ja) 1999-05-20 2000-05-19 体液性および細胞性免疫応答を増強するための安定性、生体適合性最適化アジュバント（ｓｂａ）
EP00936761A EP1183045A2 (fr) 1999-05-20 2000-05-19 Adjuvant a stabilite et biocompatibilite optimisees pour l'augmentation de la reponse immunitaire humorale et cellulaire

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19923256.3 1999-05-20
DE19923256 1999-05-20

Publications (2)

Publication Number Publication Date
WO2000071154A2 WO2000071154A2 (fr) 2000-11-30
WO2000071154A3 true WO2000071154A3 (fr) 2001-06-28

Family

ID=7908697

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2000/004565 WO2000071154A2 (fr) 1999-05-20 2000-05-19 Adjuvant a stabilite et biocompatibilite optimisees pour l'augmentation de la reponse immunitaire humorale et cellulaire
PCT/EP2000/004644 WO2000071077A2 (fr) 1999-05-20 2000-05-22 Adjuvant a stabilite et biocompatibilite optimisees (sba) pour accroitre la reponse immunitaire humorale et cellulaire

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/004644 WO2000071077A2 (fr) 1999-05-20 2000-05-22 Adjuvant a stabilite et biocompatibilite optimisees (sba) pour accroitre la reponse immunitaire humorale et cellulaire

Country Status (11)

Country Link
EP (1) EP1183045A2 (fr)
JP (1) JP2003500365A (fr)
KR (1) KR20020012221A (fr)
AU (2) AU5214200A (fr)
BR (1) BR0010823A (fr)
CA (1) CA2373239A1 (fr)
DE (1) DE10024788A1 (fr)
MX (1) MXPA01011660A (fr)
TR (1) TR200103333T2 (fr)
WO (2) WO2000071154A2 (fr)
ZA (1) ZA200109147B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9241903B2 (en) 2006-02-22 2016-01-26 Mannkind Corporation Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200103333T2 (tr) * 1999-05-20 2002-04-22 Pharmasol Gmbh Dayanıklığı ve biyolojik uygunluğu iyileştiren yardımcı ilaç (SBA)
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
ATE385193T1 (de) 2002-03-20 2008-02-15 Mannkind Corp Inhalationsgerät
ATE545434T1 (de) * 2003-10-23 2012-03-15 Novartis Vaccines & Diagnostic Stabilisierte zusammensetzungen
FR2873386B1 (fr) 2004-07-22 2011-01-14 Agence Francaise De Securite Sanitaire Des Aliments Afssa Composition vaccinale contre le rhodococcus equi
AU2005277208B2 (en) 2004-08-20 2011-11-24 Mannkind Corporation Catalysis of diketopiperazine synthesis
ES2540886T3 (es) 2004-08-23 2015-07-14 Mannkind Corporation Sales de dicetopiperazina para la administración de fármacos
EP2656836B1 (fr) * 2005-09-14 2017-07-26 MannKind Corporation Procédé de formulation de médicament sur la base de l'augmentation de l'affinité des surfaces de microparticules cristallines pour des agents actifs
EP2567723B1 (fr) 2008-06-13 2021-01-20 MannKind Corporation Inhalateur de poudre sèche et système d'administration de médicament
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
RU2470681C2 (ru) 2008-06-20 2012-12-27 Маннкайнд Корпорейшн Интерактивное устройство и способ профилирования усилий при ингаляции в реальном масштабе времени
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US8538707B2 (en) 2009-03-11 2013-09-17 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
KR20190090092A (ko) 2009-06-12 2019-07-31 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
EP2496295A1 (fr) 2009-11-03 2012-09-12 MannKind Corporation Appareil et méthode de simulation d'efforts d'inhalation
BR112012033060A2 (pt) 2010-06-21 2018-02-27 Mannkind Corp métodos de sistema de liberação de fármaco em pó seco
SG10201606220QA (en) 2011-04-01 2016-09-29 Mannkind Corp Blister package for pharmaceutical cartridges
WO2012174472A1 (fr) 2011-06-17 2012-12-20 Mannkind Corporation Microparticules de dicétopipérazine de capacité élevée
CN103945859A (zh) 2011-10-24 2014-07-23 曼金德公司 用于治疗疼痛的方法和组合物
AU2013256565B2 (en) 2012-04-30 2015-12-03 Ossur Hf Prosthetic device, system and method for increasing vacuum attachment
SG11201500218VA (en) 2012-07-12 2015-03-30 Mannkind Corp Dry powder drug delivery systems and methods
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
AU2014228415B2 (en) 2013-03-15 2018-08-09 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
CN105451716A (zh) 2013-07-18 2016-03-30 曼金德公司 热稳定性干粉药物组合物和方法
JP2016530930A (ja) 2013-08-05 2016-10-06 マンカインド コーポレイション 通気装置及び方法
WO2015148905A1 (fr) 2014-03-28 2015-10-01 Mannkind Corporation Utilisation d'insuline à action ultrarapide
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
EP3386540A1 (fr) * 2015-12-08 2018-10-17 GlaxoSmithKline Biologicals S.A. Nouvelles formulations d'adjuvant
KR102721917B1 (ko) * 2022-05-31 2024-11-04 우리이앤엘 주식회사 비타민 함유 리포좀의 제조 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19745950A1 (de) * 1997-10-17 1999-04-22 Dds Drug Delivery Service Ges Arzneistoffträgerpartikel für die gewebespezifische Arzneistoffapplikation
WO2000006120A1 (fr) * 1998-07-31 2000-02-10 Korea Institute Of Science And Technology Emulsion lipidique et nanoparticule lipidique solide en tant que transporteurs de genes ou de medicaments
DE10024788A1 (de) * 1999-05-20 2000-11-23 Gerbu Gmbh Stabilitäts-, Biokompatibilitäts-optimiertes Adjuvans (SBA) zur Erhöhung der humoralen und zellulären Immunantwort

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19745950A1 (de) * 1997-10-17 1999-04-22 Dds Drug Delivery Service Ges Arzneistoffträgerpartikel für die gewebespezifische Arzneistoffapplikation
WO2000006120A1 (fr) * 1998-07-31 2000-02-10 Korea Institute Of Science And Technology Emulsion lipidique et nanoparticule lipidique solide en tant que transporteurs de genes ou de medicaments
DE10024788A1 (de) * 1999-05-20 2000-11-23 Gerbu Gmbh Stabilitäts-, Biokompatibilitäts-optimiertes Adjuvans (SBA) zur Erhöhung der humoralen und zellulären Immunantwort

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; OLBRICH, C. ET AL: "Solid lipid nanoparticles (SLN) as vaccine adjuvant - study in sheep with a mycoplasma bovis antigen and stability testing", XP002155569, retrieved from STN *
HILGERS L A ET AL: "A novel non-mineral oil-based adjuvant. I. Efficacy of a synthetic sulfolipopolysaccharide in a squalane-in-water emulsion in laboratory animals.", VACCINE, (1994 MAY) 12 (7) 653-60., XP002155567 *
MULLER R H ET AL: "Solid lipid nanoparticles (SLN) as potential carrier for human use: interaction with human granulocytes", JOURNAL OF CONTROLLED RELEASE,NL,ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, vol. 47, no. 3, 8 September 1997 (1997-09-08), pages 261 - 269, XP004125818, ISSN: 0168-3659 *
PROC. INT. SYMP. CONTROLLED RELEASE BIOACT. MATER. (2000), 27TH, 293-294 *
SCHOLER N. ET AL: "Effect of solid lipid nanoparticles (SLN) on cytokine production and the viability of murine peritoneal macrophages.", JOURNAL OF MICROENCAPSULATION, (2000) 17/5 (639-650)., XP002155568 *
ZUR MUHLEN A ET AL: "Solid lipid nanoparticles (SLN) for controlled drug delivery--drug release and release mechanism.", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, (1998 MAR) 45 (2) 149-55., XP000738298 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9241903B2 (en) 2006-02-22 2016-01-26 Mannkind Corporation Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent

Also Published As

Publication number Publication date
MXPA01011660A (es) 2004-04-05
CA2373239A1 (fr) 2000-11-30
DE10024788A1 (de) 2000-11-23
AU5214200A (en) 2000-12-12
KR20020012221A (ko) 2002-02-15
WO2000071154A2 (fr) 2000-11-30
AU5809100A (en) 2000-12-12
JP2003500365A (ja) 2003-01-07
BR0010823A (pt) 2002-03-05
EP1183045A2 (fr) 2002-03-06
WO2000071077A2 (fr) 2000-11-30
ZA200109147B (en) 2002-05-08
TR200103333T2 (tr) 2002-04-22

Similar Documents

Publication Publication Date Title
WO2000071154A3 (fr) Adjuvant a stabilite et biocompatibilite optimisees pour l'augmentation de la reponse immunitaire humorale et cellulaire
WO2003059381A3 (fr) Préparations immunogènes et vaccins à base d'arn
EP1333858B8 (fr) Vaccins a reponse immunitaire accrue et leurs procedes de preparation
WO1999041369A3 (fr) Vecteurs de vaccins mis au point par genie genetique
HK1052629A1 (en) Proteosome influenza vaccine
WO2000056360A3 (fr) Vaccin
AU1013601A (en) Method of inducing and/or enhancing an immune response to tumor antigens
WO2005037190A3 (fr) Vaccins multiplex
WO2002034205A3 (fr) Utilisation des proteines du stress pour stimuler la reponse immunitaire
WO2000050006A3 (fr) Microemulsions a macromolecules et microparticules adsorbees
WO1999040936A3 (fr) Vaccins pneumococciques ou meningococciques formules avec l'interleukine-12
PL351893A1 (en) Vaccines
HK1067058A1 (en) Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
PT1326633E (pt) Composição compreendendo micropartículas imunogénicas
WO2007008918A3 (fr) Vaccins de virus comprenant des proteines immunomodulatrices reliees a une enveloppe, et methode d'utilisation associee
CA2272338A1 (fr) Immunisation de nourrissons
WO2003039595A3 (fr) Modeles ameliores de vaccins administrables par voie muqueuse et modes d'utilisation
WO2005007673A3 (fr) Peptides immunogenes
NO331017B1 (no) Glukan, adjuvanssammensetning omfattende glukanet samt anvendelse av glukanet for fremstilling av en mukosal administrerbar adjuvanssammensetning.
WO2002009752A3 (fr) Composants et compositions d'adjuvants immunologiques et procedes d'utilisation de ceux-ci
WO2002076485A3 (fr) Vaccin assurant la modulation entre des reponses immunitaires t1 et t2
WO2003083083A3 (fr) Procedes d'utilisation d'un ligand flt3 dans des protocoles d'immunisation
WO2000006198A3 (fr) Adjuvant comprenant un tensioactif pulmonaire
WO1997047271A3 (fr) Vaccins cellulaires immunotherapeutiques et leurs procedes de preparation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001/09147

Country of ref document: ZA

Ref document number: 200109147

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/011660

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 515530

Country of ref document: NZ

Ref document number: 1020017014653

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2373239

Country of ref document: CA

Ref document number: 2373239

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2000 619456

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001/03333

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 52142/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000936761

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020017014653

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000936761

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09959927

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1020017014653

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 2000936761

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载